IDEAYA has received the US Food and Drug Administration (FDA) clearance of an investigational new drug (IND) application to begin a Phase I clinical trial of IDE034 for multiple solid tumour types.
IDE034 is a bispecific B7 homolog 3 / protein tyrosine kinase 7 topoisomerase 1 (B7H3/PTK7 TOP1) antibody-drug conjugate (ADC).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe trial will initially assess patients with solid tumours expressing B7H3 and PTK7, including colorectal, lung, ovarian/gynaecological, and head and neck cancers, with enrolment scheduled to start in the first quarter of 2026.
Preclinical data indicate that IDE034 delivered strong anti-tumour activity and durable regressions as monotherapy in B7H3/PTK7-positive models.
IDEAYA president and CEO Yujiro Hata said: “We are excited to advance our differentiated clinical strategy with now three potentially first-in-class clinical-stage programmes focused on enhancing the efficacy of TOP1 ADCs through the PARG DNA damage response (DDR) combination mechanism.
“We believe this approach addresses a key unmet need by improving the durability of response to TOP1 payload-based ADC therapies. We are targeting to share additional preclinical data to support the PARG and TOP1 ADC combination rationale at a major medical conference in H1 2026.”
IDEAYA chief medical officer Darrin Beaupre said: “IND clearance for IDE034 is an important step in expanding our potential first-in-class TOP1 ADC clinical pipeline into bispecific, precision-guided approaches.
“IDE034 has demonstrated robust antitumour activity and selective targeting of B7H3- and PTK7-expressing solid tumour models. The high prevalence of B7H3/PTK7 co-expression in solid tumours such as lung, colorectal, and head and neck cancers underscores its broad indication potential.”
In July 2024, IDEAYA Biosciences reported positive interim data from a Phase II trial of IDE397 to treat methylthioadenosine phosphorylase (MTAP) deletion urothelial and non-small cell lung cancer (NSCLC).
ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
